semaj83/ctmatch_classification huggingface dataset:
Patient description: The patient is a 41-year-old man and a known case of Acromegaly who underwent transsphenoidal surgery 4 months ago. He came to the clinic for the follow up lab studies after his primary resection surgery. His lab study shows the IGF-1 level of 4.5 ULN adjusted by sex and age. His random GH level is 4 ug/L. The recent brain MRI confirmed the residual pituitary tumor. His past medical history is only significant for acromegaly due to pituitary adenoma and the recent surgery. After his surgery he takes only vitamin D and multivitamins.

Clinical trial eligibility criteria: eligible ages (years): 18.0-70.0,  Acromegaly Due to Pituitary Adenoma Among patients with acromegaly due to growth hormone secreting pituitary adenoma who underwent primary surgical resection, patients who fail to achieve endocrinologic remission at 3 months after surgery On brain MRI scan at 3months after surgery, residual tumor is confirmed by clinicians the definition of endocrinologic remission 1. random growth hormone level < 2.5 ug/L 2. normalization of age-matched insulin growth factor-1 level  patients with contraindication of stereotactic radiosurgery; e.g. pregnancy or planning pregnancy, or claustrophobia recurrent pituitary adenoma limited life expectancy due to systemic disease; e.g. malignant tumor, genetic disease, and terminal stage of renal or hepatic failure disability to clinic visit due to postoperative complications
Patient description: The patient is a 41-year-old man and a known case of Acromegaly who underwent transsphenoidal surgery 4 months ago. He came to the clinic for the follow up lab studies after his primary resection surgery. His lab study shows the IGF-1 level of 4.5 ULN adjusted by sex and age. His random GH level is 4 ug/L. The recent brain MRI confirmed the residual pituitary tumor. His past medical history is only significant for acromegaly due to pituitary adenoma and the recent surgery. After his surgery he takes only vitamin D and multivitamins.

Clinical trial eligibility criteria: eligible ages (years): 19.0-999.0,  Pituitary Tumor patients with pituitary somatotroph tumor and with nonfunctioning pituitary tumor in transsphenoidal pituitary surgery American society of anesthesiologists classification 1 or 2  left ventricle ejection fraction < 55% 3RD degree AV block, 2nd degree AV block with P:QRS > 3:1 serum Creatinine > 1.0mg/dl myocardial infarction or cerebral stroke in 1 yrs fever > 38C dementia, cognitive disorder, confused mental status pregnant patients allergic to propofol illiteracy or foreigners
Patient description: The patient is a 41-year-old man and a known case of Acromegaly who underwent transsphenoidal surgery 4 months ago. He came to the clinic for the follow up lab studies after his primary resection surgery. His lab study shows the IGF-1 level of 4.5 ULN adjusted by sex and age. His random GH level is 4 ug/L. The recent brain MRI confirmed the residual pituitary tumor. His past medical history is only significant for acromegaly due to pituitary adenoma and the recent surgery. After his surgery he takes only vitamin D and multivitamins.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Pituitary Disease Pituitary Incidentaloma Acromegaly Central Diabetes Insipidus Pituitary Stalk Compression Hyperprolactinaemia Cushing's Disease Pituitary Tumor Prolactinoma Subjects for this study will be recruited if they are: 1. Adults, male or female aged 18 years or older 2. diagnosed with pituitary diseases such as acromegaly, Cushing's disease, hyperprolactinemia, nonfunctioning pituitary adenoma, pituitary stalk lesions, central diabetes insipidus, and craniopharyngiomas  Patients who do not agree with the study
Patient description: The patient is a 41-year-old man and a known case of Acromegaly who underwent transsphenoidal surgery 4 months ago. He came to the clinic for the follow up lab studies after his primary resection surgery. His lab study shows the IGF-1 level of 4.5 ULN adjusted by sex and age. His random GH level is 4 ug/L. The recent brain MRI confirmed the residual pituitary tumor. His past medical history is only significant for acromegaly due to pituitary adenoma and the recent surgery. After his surgery he takes only vitamin D and multivitamins.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Pituitary Adenoma Suspected symptomatic or progressively growing pituitary adenoma Informed consent  Prolactinoma No follow-up possible Emergency surgery without informed consent or without intraoperative MRI
Patient description: The patient is a 41-year-old man and a known case of Acromegaly who underwent transsphenoidal surgery 4 months ago. He came to the clinic for the follow up lab studies after his primary resection surgery. His lab study shows the IGF-1 level of 4.5 ULN adjusted by sex and age. His random GH level is 4 ug/L. The recent brain MRI confirmed the residual pituitary tumor. His past medical history is only significant for acromegaly due to pituitary adenoma and the recent surgery. After his surgery he takes only vitamin D and multivitamins.

Clinical trial eligibility criteria: eligible ages (years): 18.0-99.0,  Sleep Apnea patients with newly diagnosed acromegaly  patients who can not undergo transsphenoidal surgery
Patient description: The patient is a 41-year-old man and a known case of Acromegaly who underwent transsphenoidal surgery 4 months ago. He came to the clinic for the follow up lab studies after his primary resection surgery. His lab study shows the IGF-1 level of 4.5 ULN adjusted by sex and age. His random GH level is 4 ug/L. The recent brain MRI confirmed the residual pituitary tumor. His past medical history is only significant for acromegaly due to pituitary adenoma and the recent surgery. After his surgery he takes only vitamin D and multivitamins.

Clinical trial eligibility criteria: eligible ages (years): 0.0-999.0,  Mucopolysaccharidosis II Documented diagnosis of MPS II confirmed by enzyme activity as measured in plasma, fibroblasts, or leukocytes 2. The subject has at least one of the neurocognitive assessments listed below, which occurred prior to age 6 and in or after 2006 in their medical records. 1. Bayley Scales of Infant and Toddler Development (BSID), any version 2. Differential Ability Scale (DAS), any version 3. Griffiths Mental Development Scale (GMDS), any version 4. Kaufman Assessment Battery for Children (KABC), any version 5. Kinder Infant Development Scale (KIDS) 6. Kyoto Scale of Psychological Development (KSPD), any version 7. Leiter International Performance Scale (LIPS), any version 8. Mullen Scales of Early Learning (MSEL), any version 9. Vineland Adaptive Behavior Scales (VABS), any version 10. Wechsler Intelligence Scale for Children (WISC), any version 11. Wechsler Preschool and Primary Scale of Intelligence (WPPSI), any version 3. If the subject has undergone hematopoietic stem cell transplantation (HSCT), they must have at least one neurocognitive assessment prior to HSCT
Patient description: The patient is a 41-year-old man and a known case of Acromegaly who underwent transsphenoidal surgery 4 months ago. He came to the clinic for the follow up lab studies after his primary resection surgery. His lab study shows the IGF-1 level of 4.5 ULN adjusted by sex and age. His random GH level is 4 ug/L. The recent brain MRI confirmed the residual pituitary tumor. His past medical history is only significant for acromegaly due to pituitary adenoma and the recent surgery. After his surgery he takes only vitamin D and multivitamins.

Clinical trial eligibility criteria: eligible ages (years): 18.0-75.0,  Acromegaly Males or females with documented diagnosis of Acromegaly, aged 18-75 years old (inclusive) at the time of informed consent 2. Patients must be on stable maximum or maximally tolerated dose of SRL (Lanreotide Autogel or Octreotide LAR, per treating physician judgment) every 28 days for a minimum of 3 months prior to screening and will be required to continue their stable dose of SRL throughout the study. Prior use of other medications for treating acromegaly is allowed but not within 6 weeks of screening. 3. At Screening, serum IGF-1 (performed at central lab) between 1.3 to 5 x ULN, inclusive, adjusted for age and sex 4. Females must be non-pregnant and non-lactating, and either surgically sterile, post-menopausal, abstinent, or using 1 highly effective method of birth control  Patients who received surgery for pituitary adenoma within the last 6 months before the trial, or planning to receive surgery during the trial 2. Patients who received radiotherapy for pituitary adenoma within the last 3 years before the trial, and/or planning to receive radiotherapy during the trial 3. Patients with pituitary tumor that, per Investigator judgement, is worsening as assessed by pituitary/sellar MRI protocol at Screen or within 6 months of screening 4. Evidence of decompensated cardiac function per medical judgement and/or NYHA class 3 or 4 5. Clinical evidence of symptomatic hyperprolactinemia that would necessitate treatment 6. Patients may not have chronic systemic use of glucocorticoids, weight loss medications or participate in weight loss programs within 2 months before randomization and during study participation. 7. Patients on anti-diabetes medication or estrogen containing medications must be on a stable dose and regimen for >= 3 months prior to screening and throughout the trial 8. Patients taking GLP-1 agonists or insulin can be allowed with prior consultation with the Sponsor Medical Monitor
Patient description: The patient is a 41-year-old man and a known case of Acromegaly who underwent transsphenoidal surgery 4 months ago. He came to the clinic for the follow up lab studies after his primary resection surgery. His lab study shows the IGF-1 level of 4.5 ULN adjusted by sex and age. His random GH level is 4 ug/L. The recent brain MRI confirmed the residual pituitary tumor. His past medical history is only significant for acromegaly due to pituitary adenoma and the recent surgery. After his surgery he takes only vitamin D and multivitamins.

Clinical trial eligibility criteria: eligible ages (years): 0.0-999.0,  Pituitary Adenoma lndicated trans-nasal trans-sphenoidal surgery for an anterior skull base tumour with preoperative baseline MRI (Centre A and B) and baseline CT (Centre A)  Previous trans-sphenoidal surgery Patients without CT, MRI or intraoperative endoscopic video
Patient description: The patient is a 41-year-old man and a known case of Acromegaly who underwent transsphenoidal surgery 4 months ago. He came to the clinic for the follow up lab studies after his primary resection surgery. His lab study shows the IGF-1 level of 4.5 ULN adjusted by sex and age. His random GH level is 4 ug/L. The recent brain MRI confirmed the residual pituitary tumor. His past medical history is only significant for acromegaly due to pituitary adenoma and the recent surgery. After his surgery he takes only vitamin D and multivitamins.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Hyponatremia Hyponatremic Pituitary Tumor Pituitary Surgery • Any adult patient with a pituitary adenoma or cyst (either non-functioning, prolactin-secreting, growth hormone secreting, ACTH (adrenocorticotropic hormone)-secreting, gonadotropin secreting, or TSH secreting) scheduled to undergo pituitary resection  Patients with a history of chronic hyponatremia Patients with a history of SIADH (syndrome of inappropriate antidiuretic hormone) , except if secondary to hypothyroidism or adrenal insufficiency, or in association with prior TSS Patients with diabetes insipidus or patients receiving DDAVP Patients without an intact thirst mechanism Patients with CKD (chronic kidney disease) stage III, IV or V Patients with untreated adrenal insufficiency or hypothyroidism Patients with class III or IV heart failure
Patient description: The patient is a 41-year-old man and a known case of Acromegaly who underwent transsphenoidal surgery 4 months ago. He came to the clinic for the follow up lab studies after his primary resection surgery. His lab study shows the IGF-1 level of 4.5 ULN adjusted by sex and age. His random GH level is 4 ug/L. The recent brain MRI confirmed the residual pituitary tumor. His past medical history is only significant for acromegaly due to pituitary adenoma and the recent surgery. After his surgery he takes only vitamin D and multivitamins.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Reconstructive Surgery After Carcinological Excision Patient eligible for reconstructive surgery after carcinological excision following a decision taken in a multidisciplinary consultation, and for whom the envisaged oral defect concerns either the soft tissues of the oral cavity and oropharynx, or the mandibular bone Scheduled post-operative radiotherapy Coverage by the Social Security system Capacity to provide informed consent  Post-traumatic substance loss (ballistic autolysis) Surgical or anesthetic contraindication (physiological age, other proposed therapeutic options) Pregnant or breastfeeding woman Subject incapable of full age or deprived of liberty Indication for chemotherapy with highly neurotoxic agents Inability to complete questionnaires or express feelings during the examination Any situation judged by the investigator as a contraindication to neurorrhaphy
Patient description: The patient is a 41-year-old man and a known case of Acromegaly who underwent transsphenoidal surgery 4 months ago. He came to the clinic for the follow up lab studies after his primary resection surgery. His lab study shows the IGF-1 level of 4.5 ULN adjusted by sex and age. His random GH level is 4 ug/L. The recent brain MRI confirmed the residual pituitary tumor. His past medical history is only significant for acromegaly due to pituitary adenoma and the recent surgery. After his surgery he takes only vitamin D and multivitamins.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Pituitary Tumor years of age or older undergoing endoscopic endonasal transsphenoidal approach to pituitary resection for pituitary tumors of any pathology for the first time  patients who do not have a working understanding of English patients with known allergy to Merocel nasal packing
Patient description: The patient is a 41-year-old man and a known case of Acromegaly who underwent transsphenoidal surgery 4 months ago. He came to the clinic for the follow up lab studies after his primary resection surgery. His lab study shows the IGF-1 level of 4.5 ULN adjusted by sex and age. His random GH level is 4 ug/L. The recent brain MRI confirmed the residual pituitary tumor. His past medical history is only significant for acromegaly due to pituitary adenoma and the recent surgery. After his surgery he takes only vitamin D and multivitamins.

Clinical trial eligibility criteria: eligible ages (years): 18.0-65.0,  Pituitary Neoplasm Adult subjects (more than 18 years of age) will be included in this study if they: 1. Have a known or suspected tumor of the pituitary gland that requires surgical resection through a transsphenoidal approach. There is no size restriction. Invasion of surrounding anatomical structures by the pituitary tumor will not be ground for screen failure/withdrawal from study. 2. Are enrolled in 03-N-0164, Evaluation and Treatment of Neurosurgical Disorders. If not enrolled, subjects will not be able to be included in the study as clinical and research procedures are done under the 03-N-0164 protocol. 3. Are able to provide written consent 4. NIH employees are included in the study Subjects will be excluded from this study if they: 1. Are unable to fit the intra-operative MRI table due to size or weight restrictions i.e morbid obesity. Patients will be anaesthetized and therefore claustrophobia will not be ground for screen failure/withdrawal from study. 2. Have an absolute contraindication to MRI imaging or MRI contrast agent according to Rad&IS screening including devices or conditions. 3. Have a variant anatomy which may, in the judgment of the operating neurosurgeon, add unacceptable risk to the placement of the endosphenoidal coil (e.g. small size of facial bones and nasal passages, unaerated sphenoid sinus etc.). 4. Are pregnant or nursing. 5. Patients older than 65 years of age. Cushing disease is rare in the older population. The Checklist is included as an attachment. This checklist is used by the investigator at the time of screening for admission to the protocol
Patient description: The patient is a 41-year-old man and a known case of Acromegaly who underwent transsphenoidal surgery 4 months ago. He came to the clinic for the follow up lab studies after his primary resection surgery. His lab study shows the IGF-1 level of 4.5 ULN adjusted by sex and age. His random GH level is 4 ug/L. The recent brain MRI confirmed the residual pituitary tumor. His past medical history is only significant for acromegaly due to pituitary adenoma and the recent surgery. After his surgery he takes only vitamin D and multivitamins.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Post Operative Care Endoscopic Skull Base Surgery Postoperative Period Has surgery for pituitary adenoma at UVA after May 1st, 2018 Has sellar and parasellar pathology ≥ 18 years old Can complete all parts of study in English  Extended approaches Use of naso-septal flap during the current surgical procedure Septoplasty Prior history of Chronic Rhinosinusitis (CRS) Prior history of sphenoidotomy < 18 years old Prisoner
Patient description: The patient is a 41-year-old man and a known case of Acromegaly who underwent transsphenoidal surgery 4 months ago. He came to the clinic for the follow up lab studies after his primary resection surgery. His lab study shows the IGF-1 level of 4.5 ULN adjusted by sex and age. His random GH level is 4 ug/L. The recent brain MRI confirmed the residual pituitary tumor. His past medical history is only significant for acromegaly due to pituitary adenoma and the recent surgery. After his surgery he takes only vitamin D and multivitamins.

Clinical trial eligibility criteria: eligible ages (years): 18.0-64.0,  Acromegaly Muscle Dysfunction Physical Activity Exercise Patients with acromegaly, of both sexes, older than 18 and younger than 65 years, either with active or controlled disease Patients who present clinical stability and who are eligible for the treatment protocol (patients with hormone deficiency will continue on replacement therapy - SILVA et al., 2013) Signature of the Informed Consent Term (TCLE)  Patients with inability to perform the 6MWT, according to ATS criteria Patients who have cognitive impairment by mini mental state examination (MEEN) Abandonment of treatment during the application of the protocol Uncontrolled hypertension (> 180/100 mmHg with medication use) Use of psychotropic drugs Any significant limitations due to osteoarthropathy History of surgery in the previous year with exercise restriction. Não Untreated hypothyroidism or hypocortisolism (HUBBLE et al., 2014) IPAQ with very active classification
Patient description: The patient is a 41-year-old man and a known case of Acromegaly who underwent transsphenoidal surgery 4 months ago. He came to the clinic for the follow up lab studies after his primary resection surgery. His lab study shows the IGF-1 level of 4.5 ULN adjusted by sex and age. His random GH level is 4 ug/L. The recent brain MRI confirmed the residual pituitary tumor. His past medical history is only significant for acromegaly due to pituitary adenoma and the recent surgery. After his surgery he takes only vitamin D and multivitamins.

Clinical trial eligibility criteria: eligible ages (years): 18.0-65.0,  Pituitary Adenoma Normal serum pituitary hormone levels or mild increase of serum prolactin. 2. Enhanced MRI shows a pituitary tumor and tumor diameter>1cm. 3. Aged between 18 and 65 years old, either sex. 4. Karnofsky performance status ≥ 70. 5. The patient has signed the informed consent  Patients concomitantly taking the psychotropic drugs. 2. Patients with parkinson disease and is taking dopaminergic agents. 3. Patients with pituitary adenoma who received Gamma knife treatment. 4. Pregnant or lactating women. 5. Patients with poor compliance, who cannot implement the program strictly. 6. History of allergic reactions attributed to compounds of similar chemical or biologic composition to cabergoline. 7. Patients with claustrophobia. -
Patient description: The patient is a 41-year-old man and a known case of Acromegaly who underwent transsphenoidal surgery 4 months ago. He came to the clinic for the follow up lab studies after his primary resection surgery. His lab study shows the IGF-1 level of 4.5 ULN adjusted by sex and age. His random GH level is 4 ug/L. The recent brain MRI confirmed the residual pituitary tumor. His past medical history is only significant for acromegaly due to pituitary adenoma and the recent surgery. After his surgery he takes only vitamin D and multivitamins.

Clinical trial eligibility criteria: eligible ages (years): 18.0-65.0,  Acute Pain Key Before surgery Body mass index (BMI) of 18.0 to 38.0 kilogram per meter square (kg/m^2) Be scheduled to undergo a primary unilateral first metatarsal bunionectomy repair, without collateral procedures, under regional anesthesia (Mayo and popliteal sciatic block) not to base wedge procedure After surgery Subject reported pain of greater than or equal to (>=) 4 on Numeric Pain Rating Scale (NPRS) and moderate or severe pain on the Verbal Categorical Rating Scale (VRS) within 9 hours after removal of the popliteal sciatic block on Day 1 Subject is lucid and able to follow commands All analgesic guidelines were followed during and after the bunionectomy Key  Before surgery History in the past 10 years of malignancy, except for squamous cell skin cancer, basal cell skin cancer, and Stage 0 cervical carcinoma in situ History of cardiac dysrhythmias requiring anti-arrhythmia treatment(s) History of abnormal laboratory results >=2.5*upper limit of normal (ULN) History of peripheral neuropathy A known or clinically suspected infection with human immunodeficiency virus or hepatitis B or C viruses Prior medical history of bunionectomy or other foot surgery on the index foot History of peptic ulcer disease, or intolerance or unwillingness to receive ibuprofen After surgery Subject had a type 3 deformity requiring a base wedge osteotomy or concomitant surgery Other protocol defined inclusion/
Patient description: The patient is a 41-year-old man and a known case of Acromegaly who underwent transsphenoidal surgery 4 months ago. He came to the clinic for the follow up lab studies after his primary resection surgery. His lab study shows the IGF-1 level of 4.5 ULN adjusted by sex and age. His random GH level is 4 ug/L. The recent brain MRI confirmed the residual pituitary tumor. His past medical history is only significant for acromegaly due to pituitary adenoma and the recent surgery. After his surgery he takes only vitamin D and multivitamins.

Clinical trial eligibility criteria: eligible ages (years): 40.0-80.0,  Asthma-COPD Overlap Syndrome Vitamin D Deficiency Cardiac Autonomic Tone • 40-80 years of age Male Middle class of socioeconomic condition Stable patients of Asthma COPD Overlap (ACO) with >4 years of disease duration Vitamin D deficient (Serum 25-hydroxycholecalciferol, 25(OH)D level < 30 ng/ml) Normal serum Ca+and inorganic phosphate level Hypertension with ACO Diabetes with ACO  Unstable patients with ACO (patients with exacerbation and medication changes in the past 30 days) With acute exacerbation of any pulmonary diseases, such as Bronchial asthma Acute respiratory tract infection Current tuberculosis Pleural effusion Emphysematous bullae Interstitial lung disease Pneumonectomy or pulmonary lobectomy Pulmonary fibrosis